Combination therapy for cancers with BRAF mutation
US11753476B2 · kind B2 · utility
0Cited by
13References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2019 |
| Grant date | Sep 12, 2023 |
| Priority date | — |
| Expiry date | Apr 8, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.